US stock · figures in US dollars · scored on full-year results
Intuitive Surgical Intuitive Surgical, Inc.
Intuitive Surgical scores 66/100 on fundamentals: in the top 19% of 503 scored S&P 500 stocks. Its strongest area is Business Strength (100/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
An expensively priced stock with healthy growth, but price fairness needs attention.
Nearby peers
Ranks #8 of 60 in Healthcare by score
One-Minute Summary
Why Intuitive Surgical scores 66
An expensively priced stock with healthy growth, but price fairness needs attention.
Business Strength
100Why 100?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 62.5% over 4 years: customers keep spending more with this company.
Profit climbed about 64.5% over 4 years: the business keeps more money as it grows.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 41.9% over the last 8 quarters: customers keep spending more with this company.
Profit grew about 44.8% over the last 8 quarters: the business is keeping more of what it earns.
Financial Safety
N/ACash & Dividends
67Why 67?
No data: Cash & Cash Equivalents
Show 2 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is down about 19.1% over the past year.
Risk
83Why 83?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Intuitive Surgical (ISRG) scores 66/100 (Okay) on Score Your Stock's educational fundamentals model: in the top 19% of 503 scored S&P 500 stocks.
Its strongest pillar is Business Strength (100/100); its weakest is Price Fairness (0/100).
Intuitive Surgical ranks #8 of 60 scored Healthcare stocks on Score Your Stock.
Intuitive Surgical (ISRG) has not paid a dividend in the last 12 months.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy ISRG. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Intuitive Surgical (ISRG) is a Healthcare company (Medical Instruments & Supplies). On Score Your Stock's fundamentals check, it scores 66/100, rated Okay. Its biggest strength is Business Strength (100/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 52 years of its current profit to buy (P/E 51.6×). Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/isrg-intuitive-surgical
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Current Ratio | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 11.6b | US$ 3.0b | US$ 4.1b | US$ 3.6b | US$ -491.5m | US$ 3.0b | US$ 16.0b | US$ 8.4b | US$ 2.5b | US$ 19.3b | US$ 3.2b | US$ 2.1b | - | 19% | 26% | 3.3× | - | - | - | - |
| 2025 | US$ 10.1b | US$ 2.9b | US$ 3.0b | US$ 2.5b | US$ -539.8m | US$ 3.4b | US$ 17.8b | US$ 9.8b | US$ 2.0b | US$ 20.5b | US$ 2.5b | US$ 1.8b | US$ 0.0m | 16% | 28% | 4.9× | 0% | 69.9× | 11.2× | 2.4 |
| 2024 | US$ 8.4b | US$ 2.3b | US$ 2.4b | US$ 1.3b | US$ -1.1b | US$ 2.0b | US$ 16.4b | US$ 7.1b | US$ 1.7b | US$ 18.7b | US$ 2.2b | US$ 1.5b | US$ 0.0m | 14% | 28% | 4.1× | 0% | 82.2× | 11.6× | 2.5 |
| 2023 | US$ 7.1b | US$ 1.8b | US$ 1.8b | US$ 749.6m | US$ -1.1b | US$ 2.8b | US$ 13.3b | US$ 7.9b | US$ 1.7b | US$ 15.4b | US$ 2.0b | US$ 1.2b | US$ 0.0m | 14% | 25% | 4.8× | 0% | 66.1× | 8.9× | 1.8 |